Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.
The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.
Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.
The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.
Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.
For more updates and detailed financial information, visit Acrivon's investor relations page.
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
Acrivon Therapeutics reported its first quarter 2024 financial results and business highlights on May 14, 2024. The company, which leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines, made significant strides in its clinical and preclinical pipeline.
Key achievements include the validation of the AP3 platform's ACR-368 OncoSignature assay, demonstrating a 50% overall confirmed response rate in patients with ovarian and endometrial cancer. The company has also accelerated the IND timeline for ACR-2316, a new WEE1/PKMYT1 inhibitor, with clinical trials expected to begin in Q4 2024. Financially, Acrivon reported a net loss of $16.5 million for Q1 2024, compared to $12.8 million in Q1 2023. The company raised $130 million in a private placement, extending its cash runway into H2 2026.
FAQ
What does Acrivon Therapeutics specialize in?
What is Acrivon's leading drug candidate?
What is the Acrivon Predictive Precision Proteomics (AP3) platform?
Has Acrivon received any regulatory designations for its drugs?
What recent achievements has Acrivon announced?
What is the status of Acrivon's ACR-2316 drug candidate?
How does the AP3 platform contribute to drug development?
What is the significance of the ACR-368 OncoSignature test?
How well-funded is Acrivon for its ongoing and future projects?